Immune system 'atlas' will speed detection of kidney transplant

February 23, 2009

Scientists at the Stanford University School of Medicine and Lucile Packard Children's Hospital have devised a new way to decode the immune signals that cause slow, chronic rejection of all transplanted kidneys. They've created an immune-system "atlas" that will improve doctors' ability to monitor transplanted organs and shed light on the mechanisms of gradual, cumulative kidney malfunction after transplant.

"The reason chronic injury occurs in transplanted organs is really a mystery," said senior study author Minnie Sarwal, MD, PhD, professor of pediatrics at the School of Medicine and a nephrologist at Packard Children's Hospital. "Even patients who receive an organ from an identical twin develop chronic rejection."

The findings will be published online Feb. 23 in the Proceedings of the National Academy of Sciences.

Before an organ transplant, doctors check for compatibility between the donor's and recipient's immune systems, Sarwal said. They examine the genes encoding small proteins, called human leukocyte antigens, that label the exterior of every cell. These proteins are the immune system's main mechanism for distinguishing "self" from "non-self" tissues. Only identical twins have perfectly matched human leukocyte antigens; for other organ recipients, doctors use a donor with the closest match they can find. After transplant, an organ recipient receives strong drugs that reduce the body's ability to crank out antibodies — immune "search-and-destroy" markers — against the donated kidney.

But the fact that chronic organ rejection occurs even between twins suggests the immune system is doing more than keeping tabs on human leukocyte antigens.

The Stanford team set out to find what that was. The researchers devised a first-of-its-kind method to catalog every one of the antibodies attacking donated kidneys after transplant. They tracked evidence of all types of immune system attack by comprehensively comparing antibody levels in 18 kidney recipients before and after transplant. To do this, they melded two biological sleuthing systems, first comparing all proteins in the subjects' blood to an array of more than 5,000 human proteins, then running the results from that analysis through a genetic database that showed which blood proteins were antibodies designed to attack the donated kidney.

"This is pretty revolutionary," Sarwal said. "It opens the door to a lot of exciting work to personalize how we monitor these patients." The new findings will allow inexpensive, noninvasive blood tests that show whether a donated kidney is infected, undergoing acute rejection or accruing chronic injuries that could cause long-term malfunction, she said.

"An individual's antibody profile is a new aspect of human physiology that can now be surveyed in an unbiased way, the same way genes can," said co-senior author Atul Butte, MD, PhD, assistant professor of medical informatics and of pediatrics. "That's very exciting." Butte is also a member of the Stanford Cancer Center. Unlike genes, the body's antibodies change over time, a factor that could improve the effectiveness of personalized medicine, Butte said.

The team's raw data on antibody profiles is now publicly available to other scientists through the Gene Expression Omnibus database maintained by the National Center for Biotechnology Information, a division of the National Library of Medicine.

In addition to improving patient monitoring, the team's comprehensive list of anti-kidney antibodies will spur research on the mechanisms of chronic kidney rejection. For example, the study establishes for the first time what part of the kidney causes the largest immune response after transplant.

"To our great surprise, the most immunogenic region of the kidney is the renal pelvis," Sarwal said. The renal pelvis is the cavity deep inside the organ that collects urine and funnels it toward the bladder. The next-largest immune responses were observed at the cortex and glomerulus, regions of the kidney with large blood supplies and extensive exposure to the recipient's immune system. The next step in understanding chronic organ rejection will be to identify which specific anti-kidney antibodies are the most reliable harbingers of renal malfunction, Sarwal said.

"If we can correlate these antibodies with clinical events in the organ, we'll have the tools to extend the life of kidney transplants," Sarwal concluded.

Source: Stanford University Medical Center


Rank not rated yet
Relevant PhysicsForums posts

More news stories

Team isolates nerve cells involved in storing long term memory and gene proteins associated with them

(Medical Xpress) -- A research team in Taiwan has succeeded in isolating two nerve cells in fruit fly brains that are believed to be the major players in allowing for the formation of long term memories. Furthermore, ...

Medicine & Health / Neuroscience

created 55 minutes ago | popularity 5 / 5 (3) | comments 0 | with audio podcast report

News of plaque-clearing drug tops week of major advances against Alzheimer's disease

In the last eight days, scientists have delivered a powerful one-two punch in the fight to defeat Alzheimer's disease. At the same time, the White House and members of Congress are proposing increases in Alzheimer's research ...

Medicine & Health / Diseases

created 51 minutes ago | popularity not rated yet | comments 1

To avoid early labor and delivery, weight and diet changes not the answer

One of the strongest known risk factors for spontaneous or unexpected preterm birth – any birth that occurs before the 37th week of pregnancy, most often without a known cause – is already having had one. For women ...

Medicine & Health / Health

created 4 minutes ago | popularity not rated yet | comments 0 | with audio podcast

Joint patent for using the BRCA1 gene as a therapy for cardiovascular disease

St. Michael's Hospital and King Saud University have received their first joint U.S. patent to use the BRCA1 gene as a therapy for cardiovascular disease.

Medicine & Health / Genetics

created 20 minutes ago | popularity not rated yet | comments 0

S.Africa in $208 mln AIDS drug venture with Swiss Lonza

South Africa on Friday unveiled plans for a 1.6 billion rand ($208 million, 157 million euro) pharmaceutical plant, in a joint venture with Swiss biochemicals group Lonza to produce anti-AIDS drugs.

Medicine & Health / HIV & AIDS

created 1 hour ago | popularity not rated yet | comments 0


The power of estrogen -- male snakes attract other males

A new study has shown that boosting the estrogen levels of male garter snakes causes them to secrete the same pheromones that females use to attract suitors, and turned the males into just about the sexiest ...

Could Venus be shifting gear?

(PhysOrg.com) -- ESA’s Venus Express spacecraft has discovered that our cloud-covered neighbour spins a little slower than previously measured. Peering through the dense atmosphere in the infrared, the ...

Experts reveal how plants don't get sunburn

(PhysOrg.com) -- Experts at the University of Glasgow have discovered how plants survive the harmful rays of the sun.

Fool's gold may prove an unlikely alternative to overexploited catalytic materials

Catalytic materials, which lower the energy barriers for chemical reactions, are used in everything from the commercial production of chemicals to catalytic converters in car engines. However, with current catalytic materials ...

SLAC, Stanford team focuses on high-energy electrons to treat cancer

Accelerator physicists at SLAC and cancer specialists from Stanford are working on a new technology that could dramatically reduce the time needed for cancer radiation treatments. The team ran an initial experiment ...

Unpicking HIV’s invisibility cloak

Drug researchers hunting for alternative ways to treat human immunodeficiency virus (HIV) infections may soon have a novel target—its camouflage coat. HIV hides inside a cloak unusually rich in a sugar ...